# N4 Pharma updates on patent filing

- Link: https://www.directorstalkinterviews.com/n4-pharma-updates-on-patent-filing/4121088549
- Published: 2022-11-01T07:06:09+00:00
- Author: Amilia Stone

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has provided an update
on its patent application for Nuvec®, filed in March 2020 (no. PCT/GB2021/050960
Gene Therapy Vectors).

The Company originally filed a Patent Cooperation Treaty (“PCT”) patent application
for Nuvec® to be used to manufacture viral vectors and to make viral vectors more
efficient in applications such as ex-vivo gene therapy treatments. Under the terms
of the PCT application process and following feedback from an international patent
search, the Company is now making enhancements to the claims of the applications
in the territories in which it wishes to gain patent protection. N4 pharma is pursuing
this patent application which, if granted, would be in addition to the patents it
has exclusively licensed from the University of Queensland.

The Company has decided to focus its claims on the use of the specific spiky properties
of Nuvec™ to load and transfect viral vectors, especially adenoviral vectors and
lentiviral vectors. This is based on feedback from the examiner and further work
the Company has done that has shown how combining Nuvec® with adenoviral vectors(
in addition to its earlier work on lentiviral vectors) can lead to an improvement
in vector performance and a reduction in the amount of the viral vector needed.

The Company has filed ongoing patent applications in the following territories: 
Europe (including UK); USA; Japan; India and Canada. It will also file applications
in Australia and China in due course. 

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:**
> “We are seeking to refine our claims to give this patent the greatest chance of
> being granted in a field with strong commercial opportunity. Should the patent
> be granted in these territories it would mirror the regions granted for the main
> patent which the Company has licensed from the University of Queensland and further
> strengthen the commercial protection of Nuvec®.”

Share on: